🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Honored/humbled for kind award by ECOG-ACRIN Cancer Research Group Am so excited to work in this amazing community of stellar leaders, staff, investigators aiming to inform practice & help patients! Fred Hutch Cancer Center Dr. Tom Lynch Nicole D. Fleming MD Hsieh Lab Julie Gralow Clifford Hudis Lynn Schuchter Naomi Haas

Congratulations Petros Grivas 🥳🥳🥳 So well deserved!! 🎖️ University of Washington Fred Hutch Cancer Center ECOG-ACRIN Cancer Research Group

Congratulations, Dr. Joan Schiller! You are more than #remarkable!

Congrats to Petros Grivas on this well-deserved recognition!

Had a great time at ECOG-ACRIN this week presenting a machine learning project studying tumor network architecture ECOG-ACRIN Cancer Research Group Radiation Oncology & Molecular Radiation Sciences Johns Hopkins Kimmel Cancer Center

Great spring ECOG-ACRIN Cancer Research Group mtg with colleagues from med-, rad-, and surg-onc, + other clinical trialists! Got to share an update for The PUMP Trial which will answer the 5 decade old question of whether HAI improves OS for unresectable CRLM - EA2222 accruing at 23 high volume centers.

The #ComboMATCH Study, led by researchers from Stanford Cancer Institute, MD Anderson Cancer Center, Penn Medicine - Abramson Cancer Center, & @NCItreatment, is testing new combinations of anti-#cancer drugs, based on the characteristics of patients’ tumors. Learn more: bit.ly/ComboMATCH #PrecisionMedicine

EA8192, led by Jean Hoffman-Censits and Petros Grivas, is a phase II/III #clinicaltrial of durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. For more: bit.ly/ea8192-trial #blcsm

The PrE1702 #RealWorldData research study is evaluating how well osimertinib with or without chemotherapy works to control EGFR-positive #LungCancer in patients not participating in a clinical trial. Learn more: bit.ly/pre1702-study #LCSM #RWD #RWE

Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/indicate-trial #pcsm #ProstateCancerAware

#ClinicalTrial EAQ222CD/CostCOM, led by Gelareh Sadigh, MD of UCI Health, is testing the effectiveness of cost communication & financial navigation in patients with cancer. If you have any newly diagnosed solid cancer, you may be able to participate. bit.ly/EAQ222CD

Have you had surgery for squamous cell carcinoma of the head and neck (#HNSCC) that has come back? If so, you may be able to participate in this study of a potential new treatment. Learn more: bit.ly/ea3191-study #HeadAndNeckCancer #HNCA

The EA8211/SOAR clinical study is testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. Learn more: bit.ly/ea8211-study #kcsm

#ClinicalTrial EA2222/PUMP, led by Michael Lidsky, MD, FACS, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump

ECOG-ACRIN Cancer Research Group GI Committee is honored to have such great participation from PanCAN Cholangiocarcinoma Foundation HopeForStomachCancer and our advocates. Listening to the voices of the people we care for makes us better clinicians, researchers and people. Kim Reiss Binder (Kim Reiss)

#ClinicalTrial EA6141 is testing combination therapy with ipilimumab, nivolumab, & sargramostim in advanced #melanoma. As May is #MelanomaAwarenessMonth, learn more about this important trial: bit.ly/ea6141melanoma cc: Ahmad Tarhini,DF/HCC #MelanomaAwareness

The EAA173/DETER-SMM #ClinicalTrial is exploring new treatments for patients with high-risk #SmolderingMyeloma. Interested in learning more? Click here: bit.ly/eaa173detersmm cc: Natalie Callander, Mike Thompson, MD, PhD, FASCO, Vincent Rajkumar, Yelak Biru

ICYMI: PrE0403 manuscript published in Blood Journal by Dr. Portell UVA Cancer Center and team. Learn about this phase II study of #venetoclax added to bendamustine and obinutuzumab in patients w/ high-risk follicular #Lymphoma as front-line therapy here: rdcu.be/elII2

#ClinicalTrial MM1OA-EA02, led by Jessica Altman, MD of Lurie Cancer Center, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/ea3211-study #BloodCancer #leukemia

#ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of Duke Radiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: bit.ly/gable-trial